About Gentronix
Gentronix is a Healthcare company based in Alderley Edge (United Kingdom) founded in 1999, and was acquired by Scantox in September 2024. In-vitro and in-vivo genetic toxicology screening services are provided. The company has 1 employees. Gentronix offers products and services including Genetic Toxicology Testing, GLP Genotoxicity Services, Skin Toxicology Services, and Flow Cytometry Services. Its focus areas include Biopharma Outsourcing, CRO, Preclinical Studies and Diversified. Its legal entity is GENTRONIX LIMITED.
Company details
Gentronix provides services and solutions to help organisations optimise the development of drugs and other chemicals, by reducing attrition due to toxicity thus ensuring safer products across a wide range of chemistry driven industries. Provide contract services for genotoxicity using patented human cell GADD45a reporter, GreenScreen HC and BlueScreen HC assays and related assays including Micronucleus and Ames MPF. Offerings include - GreenScreen HC, BlueScreen HC, Ames MPF, Ames bacterial reverse mutation assay (OECD 471 ), In Vitro Mammalian Cell Micronucleus Test (OECD 487), MicroFlow Micronucleus Test, Micronucleus Test in vivo, Comet Assay, H2AX by Flow Cytometry, Apoptosis Suite, Flow Cytometry Services and Predictive Toxicology Services. Serves - Pharmaceutical Industry, Chemical Industry, Agrochemical, Fragrances and Flavours, Personal Care Products, Consumer Products, Biomaterials, Biomedical Devices and Contract Research Organisations.
- Headquarters Alderley Edge, United Kingdom
- Employees 1
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website gentronix.co.uk
- Social LinkedIn X
- Acquired by Scantox (Sep 2024)
- Legal Name Gentronix Limited
- Date of Incorporation 15 Jul, 1999
- Jurisdiction ALDERLEY EDGE, CHESHIRE, ENGLAND
Products & Services of Gentronix
Gentronix offers a comprehensive portfolio of products and services, including Genetic Toxicology Testing, GLP Genotoxicity Services, Skin Toxicology Services, and Flow Cytometry Services.
Screens for genotoxic hazards in chemicals using rapid assays.
Conducts GLP-compliant studies for gene mutation and safety.
Assesses skin irritation and sensitisation potential in vitro.
Delivers endpoints for toxicological hazard identification.
Funding Insights of Gentronix
- Total Rounds 3
- Last Round Unspecified — $938,374
- First Round $1.93M
(Mar 2007)
- Investors Count 2
All 3 funding rounds of Gentronix with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
3 investors in total: 3 institutional.
Investors in Gentronix
Gentronix has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Mercia, Scantox and NVM Private Equity.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity investments are managed across the UK. | 1984 | nvm.co.uk | Newcastle Upon Tyne, United Kingdom | |
Investment management services are provided by Mercia to various clients. | 1982 | mercia.co.uk | ||
Laboratory focused on providing pharmacology, toxicology, and histopathology services | 1977 | scantox.com | Lille Skensved, Denmark |
Investor details for Gentronix
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Gentronix
22 people are tracked at Gentronix (18 in leadership, 1 in board & advisors, 3 in team); the tracked headcount is 1.
| Name | Role | Group |
|---|---|---|
Jodie Ball | Study Director | Leadership |
Alicia Rosell Hidalgo | Study Director | Leadership |
Julie Hayes | Study Director | Leadership |
Eleanor Madders | Study Director | Leadership |
Heather Scott | Study Director | Leadership |
Karen Philp | Study Director | Leadership |
Emma Goodhead | Study Director | Leadership |
Gary Henzell | Study Director | Leadership |
Jo Walker | Study Director | Leadership |
Katie Clare | Study Director | Leadership |
Emily Smith | Study Director | Leadership |
Chris Mee | Senior Study Director | Leadership |
Nick Billinton | Chief Scientific Officer | Leadership |
Laura Hinton | COO | Leadership |
John Yates | CFO | Leadership |
Matt Tate | CEO | Leadership |
Darryl White Fca | Chief Financial Officer | Leadership |
Glyn Colley | Head Of Facilities | Leadership |
Alan Morgan | Chairman | Board & advisors |
Mark Murphy | Senior Scientist | Team |
2 more people are available in the full profile.
Complete people profiles for Gentronix
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Gentronix
4 dated milestones of Gentronix across 25 years, from founding to its latest funding, stage changes and deals.
- Founded Gentronix is founded.
- Funding First funding round of $1.9M.
- Funding Latest funding round, Unspecified, of $938K.
- Exit Acquired by Scantox.
Web traffic of Gentronix
The website of Gentronix (gentronix.co.uk) receives about 3.2K visits a month.
- Monthly visits3.2K
▼ 44.3% vs previous month
Websites whose visitors overlap most with Gentronix. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| cyprotex.com | 100% | 2.4K | #9,067,152 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Gentronix
Complete news archive for Gentronix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Gentronix
Gentronix was founded in 1999 and raised its 1st funding round 8 years after it was founded.
Gentronix is headquartered in Alderley Edge, United Kingdom. It is registered at Alderley Edge, Cheshire, United Kingdom.
Gentronix has 1 employees.
Gentronix provides services and solutions to help organisations optimise the development of drugs and other chemicals, by reducing attrition due to toxicity thus ensuring safer products across a wide range of chemistry driven industries. Provide contract services for genotoxicity using patented human cell GADD45a reporter, GreenScreen HC and BlueScreen HC assays and related assays including Micronucleus and Ames MPF. Offerings include - GreenScreen HC, BlueScreen HC, Ames MPF, Ames bacterial reverse mutation assay (OECD 471 ), In Vitro Mammalian Cell Micronucleus Test (OECD 487), MicroFlow Micronucleus Test, Micronucleus Test in vivo, Comet Assay, H2AX by Flow Cytometry, Apoptosis Suite, Flow Cytometry Services and Predictive Toxicology Services. Serves - Pharmaceutical Industry, Chemical Industry, Agrochemical, Fragrances and Flavours, Personal Care Products, Consumer Products, Biomaterials, Biomedical Devices and Contract Research Organisations.
Gentronix offers Genetic Toxicology Testing, GLP Genotoxicity Services, Skin Toxicology Services, and Flow Cytometry Services.
Gentronix has 3 investors. Key investors include Mercia, Scantox, and NVM Private Equity.
Gentronix operates through Gentronix Limited.
Yes. Gentronix was acquired by Scantox in September 2024.